Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS




Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content

15 Dec 2025
// RAPS
https://www.raps.org/news-and-articles/news-articles/2025/12/fda-proactively-reached-out-to-janssen-to-offer-a

28 Nov 2025
// EMA
https://www.ema.europa.eu/en/documents/overview/imaavy-epar-medicine-overview_en.pdf

07 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/07/3145711/0/en/Data-published-in-The-New-England-Journal-of-Medicine-demonstrate-RYBREVANT-amivantamab-plus-LAZCLUZE-lazertinib-could-re-set-survival-expectations-in-first-line-EGFR-mutated-advan.html

25 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/25/3104815/0/en/Nipocalimab-showed-greater-sustained-disease-control-versus-approved-FcRn-blockers-for-generalised-myasthenia-gravis-gMG-at-multiple-timepoints-over-24-weeks-in-newly-published-ind.html

15 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/15/3099407/0/en/Investigational-combination-of-first-in-class-bispecific-antibodies-TALVEY-talquetamab-and-TECVAYLI-teclistamab-shows-deep-and-durable-responses-in-heavily-pretreated-multiple-myel.html

12 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/12/3098040/0/en/Significant-efficacy-benefit-of-IMBRUVICA-ibrutinib-plus-venetoclax-versus-acalabrutinib-plus-venetoclax-in-frontline-treatment-of-patients-with-chronic-lymphocytic-leukaemia-sugge.html
ABOUT THIS PAGE
Janssen-Cilag is a supplier offers 1 products (APIs, Excipients or Intermediates).
Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN BORGO SAN MICHELE, ITALY bulk offered by Janssen-Cilag